Research Communications of the 27(th) ECVIM-CA Congress: Intercontinental, Saint Julian's, Malta, 14th to 16th September 2017

The efficacy population included 174 telmisartan and 88 placebo cats. Age, body weight, breed distribution, HT causes, and baseline SBP were similar in both groups (baseline SBP: telmisartangroup: 179 ( AE 9.9) mmHg; placebo-group: 177 ( AE 10.1) mmHg). Telmisartan treatment gave rise to a significantly larger reduction in mean SBP (relative to baseline) when compared to placebo on day 14 (À19 AE 22.0 mmHg, n = 174 vs À9 AE 17.7 mmHg, n = 88; P < 0.0001). At day 28, the data from 9 and 1 cats were excluded and that of two and two cats were imputed giving reduction in SBP relative to baseline of À25 AE 22.8 mmHg, (n = 165) and À11 AE 16.4 mmHg, (n = 87) for the telmisartan and placebo groups respectively. The proportion of cats with SBP reduction >20 mmHg between baseline and day 28 was 27.6% in the placebo group and 54.6% in the telmisartan group. The mean SBP decrease in the telmisartan group on day 120 was 28 AE 26.9 mmHg relative to baseline (n = 144). Adverse events were evenly distributed in both groups during the efficacy phase and were as would be expected for elderly cats suffering from CKD and other diseases of aging in the extended use phase.